NASDAQ:ONVO Organovo Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Organovo Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.95 -0.25 (-3.47 %) (As of 09/21/2020 01:23 PM ET) Add Compare Share Today's Range$6.95Now: $6.95▼$7.2650-Day Range$0.56MA: $10.00▼$15.3452-Week Range$3.87Now: $6.95▼$18.60Volume243 shsAverage Volume62,953 shsMarket Capitalization$45.39 millionP/E RatioN/ADividend YieldN/ABeta0.91 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Organovo. Previous Next 2.5 Community Rank Outperform VotesOrganovo has received 193 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrganovo has received 192 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrganovo has received 50.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote “Outperform” if you believe ONVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrganovo does not currently pay a dividend.Dividend GrowthOrganovo does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organovo insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Organovo is held by insiders. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioOrganovo has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONVO Previous Symbol CUSIPN/A CIK1497253 Webwww.organovo.com Phone858-224-1000Debt Debt-to-Equity RatioN/A Current Ratio30.54 Quick Ratio30.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.20 million Price / Sales20.63 Cash FlowN/A Price / Cash FlowN/A Book Value$4.08 per share Price / Book1.70Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-18,710,000.00 Net Margins-798.68% Return on Equity-54.41% Return on Assets-49.24%Miscellaneous Employees70 Outstanding Shares6,531,000Market Cap$45.39 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $6.95 -0.25 (-3.47 %) (As of 09/21/2020 01:23 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ONVO News and Ratings via Email Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Organovo (NASDAQ:ONVO) Frequently Asked Questions How has Organovo's stock been impacted by COVID-19? Organovo's stock was trading at $5.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONVO stock has increased by 33.7% and is now trading at $6.95. View which stocks have been most impacted by COVID-19. When is Organovo's next earnings date? Organovo is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Organovo. How were Organovo's earnings last quarter? Organovo Holdings Inc (NASDAQ:ONVO) announced its quarterly earnings results on Monday, August, 10th. The medical research company reported ($0.40) earnings per share for the quarter. Organovo had a negative net margin of 798.68% and a negative return on equity of 54.41%. View Organovo's earnings history. When did Organovo's stock split? How did Organovo's stock split work? Shares of Organovo reverse split before market open on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split. Are investors shorting Organovo? Organovo saw a decline in short interest in August. As of August 31st, there was short interest totaling 124,100 shares, a decline of 90.9% from the August 15th total of 1,370,000 shares. Based on an average daily volume of 77,900 shares, the short-interest ratio is currently 1.6 days. Currently, 1.9% of the shares of the stock are short sold. View Organovo's Short Interest. Who are some of Organovo's key competitors? Some companies that are related to Organovo include GENFIT S A/ADR (GNFT), Axcella Health (AXLA), Ayala Pharmaceuticals (AYLA), Fennec Pharmaceuticals (FENC), INmune Bio (INMB), LogicBio Therapeutics (LOGC), Lineage Cell Therapeutics (LCTX), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), Gritstone Oncology (GRTS), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), La Jolla Pharmaceutical (LJPC), Champions Oncology (CSBR) and Solid Biosciences (SLDB). View all competitors. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Novavax (NVAX), Micron Technology (MU) and Opko Health (OPK). Who are Organovo's key executives? Organovo's management team includes the following people: Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)Mr. Craig Kussman, Chief Financial Officer (Age 60)Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)Mr. Paul Gallant, Gen. Mang. (Age 54)Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications What is Organovo's stock symbol? Organovo trades on the NASDAQ under the ticker symbol "ONVO." Who are Organovo's major shareholders? Organovo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (7.50%), WINTON GROUP Ltd (0.18%), Jane Street Group LLC (0.10%), Avantax Advisory Services Inc. (0.08%), UBS Group AG (0.07%) and Commonwealth Equity Services LLC (0.07%). View institutional ownership trends for Organovo. Which institutional investors are selling Organovo stock? ONVO stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., WINTON GROUP Ltd, and Commonwealth Equity Services LLC. View insider buying and selling activity for Organovo. Which institutional investors are buying Organovo stock? ONVO stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Avantax Advisory Services Inc., and UBS Group AG. View insider buying and selling activity for Organovo. How do I buy shares of Organovo? Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Organovo's stock price today? One share of ONVO stock can currently be purchased for approximately $6.95. How big of a company is Organovo? Organovo has a market capitalization of $45.39 million and generates $2.20 million in revenue each year. Organovo employs 70 workers across the globe. What is Organovo's official website? The official website for Organovo is www.organovo.com. How can I contact Organovo? Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
